Cadence Pharmaceuticals, Inc. ("Cadence") hosted an Analyst and Investor Day on December 6, 2012. A copy of the slides used during the event is attached as Exhibit 99.1 to this Current Report on Form 8-K, and Theodore R. Schroeder, President and Chief Executive Officer of Cadence, and other executive officers expect to use selections from these slides at various upcoming meetings.

In accordance with General Instruction B.2. of Form 8-K, the information under Items 7.01 and 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof, except as expressly set forth by specific reference to Items 7.01 and 9.01 to this Current Report on Form 8-K in such filing.

By filing this information, Cadence makes no admission as to the materiality of any information in this report. The information contained in this report and the exhibit hereto is intended to be considered in the context of Cadence's filings with the Securities and Exchange Commission and other public announcements that Cadence makes, by press release or otherwise, from time to time. Cadence undertakes no duty or obligation to publicly update or revise the information contained in this report or the exhibit hereto, although it may do so from time to time as its management believes is appropriate. Any such updating may be made through the filing of other reports or documents with the Securities and Exchange Commission, through press releases, through its website or through other public disclosure.

(d) Exhibits.

     Exhibit
     Number                       Description of Exhibit
      99.1     Analyst and Investor Day Presentation, dated December 6, 2012